Clinical Trials
53 trialsRevlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Astex Pharmaceuticals, Inc.
Kid-MaCareOnco
University Hospital, Basel, Switzerland
SELF-BREATHE RCT for Chronic Breathlessness
King's College Hospital NHS Trust
STONE
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
AstraZeneca
Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors
Rigshospitalet, Denmark
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
Tanabe Pharma America, Inc.
IRMYG
Centre Hospitalier Universitaire de Saint Etienne
POM Renal
Celgene
Mesenchymal Stem Cells After Renal or Liver Transplantation
University of Liege
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
LVPK
BTG International Inc.
OPTIMAL
Oxford University Hospitals NHS Trust
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
OPTI-AGED
Centre Hospitalier Universitaire de Saint Etienne
Study of Copanlisib in Hepatic or Renal Impairment
Bayer
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Novartis
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Massachusetts General Hospital
RENAL
Celgene
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Celgene
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Dartmouth-Hitchcock Medical Center
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Amgen
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Amgen
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Bayer
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Poitiers University Hospital
EuLITE
University Hospital Birmingham
Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
Children's Oncology Group
JASINT1
Pierre Fabre Medicament
Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
Novartis
RENVEL
PETHEMA Foundation
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
Merck Sharp & Dohme LLC
Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer
Uppsala University
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
AstraZeneca
TOP
AbbVie
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
BTG International Inc.
Pharmacokinetics in Subjects With Renal Impairment
Merck KGaA, Darmstadt, Germany
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma Inc
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
National Cancer Institute (NCI)
Safinamide Renal Impairment Trial
Newron Pharmaceuticals SPA
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure
National Institute of Allergy and Infectious Diseases (NIAID)
Bortezomib-Dexamethasone-Doxorubicin-Study
Austrian Forum Against Cancer